|
000
| 01834cam 2200325zi 4500 |
|---|
| 001 | 9.883873 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107170713 |
|---|
| 006 | m o d f |
|---|
| 007 | cr |n||||||||| |
|---|
| 008 | 200123s1986 onc|||| o f00| 0|eng d |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aRG47-19/1986E-PDF |
|---|
| 245 | 00|aPossible "costs" and "savings" to the provinces of Bill C-22. |
|---|
| 264 | 1|a[Ottawa] : |bConsumer and Corporate Affairs Canada, Bureau of Policy Coordination = Consommation et corporations Canada, Bureau de la coordination des politiques, |c[1986] |
|---|
| 300 | |a1 online resource (5 pages) |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aDigitized edition from print [produced by Innovation, Science and Economic Development Canada]. |
|---|
| 520 | |a"Bill C-22 provides for a transitional phase-in of the periods of market exclusivity. Because provincial governments have been expecting a number of generic drugs to be on the market sooner than the Bill provides for, there will be transitional adjustment assistance to the provincial governments of $100 million over 4 years. This note derives the possible "cost" estimate based on a "worst case scenario" basis. In addition, it reports the possible savings to consumers due to the presence of the Drug Prices Review Board"--Introduction. |
|---|
| 610 | 10|aCanada. |tPatent Act. |
|---|
| 650 | 0|aDrugs|xPrices|zCanada. |
|---|
| 650 | 0|aPatent licenses|zCanada. |
|---|
| 650 | 6|aMédicaments|xPrix|zCanada. |
|---|
| 650 | 6|aLicences de brevets|zCanada. |
|---|
| 710 | 1 |aCanada. |bConsumer and Corporate Affairs Canada, |eissuing body. |
|---|
| 856 | 40|qPDF|s691 KB|uhttps://publications.gc.ca/collections/collection_2021/isde-ised/RG47-19-1986-eng.pdf |
|---|